Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have received an average recommendation of "Buy" from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $11.80.
IMUX has been the subject of several recent analyst reports. HC Wainwright initiated coverage on shares of Immunic in a report on Monday, November 25th. They issued a "buy" rating and a $10.00 price target for the company. Leerink Partners reissued an "outperform" rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a "strong-buy" rating in a report on Monday, September 16th. Leerink Partnrs raised shares of Immunic to a "strong-buy" rating in a report on Monday, September 9th. Finally, StockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a report on Monday, November 11th.
View Our Latest Analysis on IMUX
In other news, Director Richard Alan Rudick acquired 87,300 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares of the company's stock, valued at $100,395. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.00% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Immunic in the third quarter valued at about $50,000. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after purchasing an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after buying an additional 42,383 shares during the last quarter. Finally, State Street Corp lifted its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after buying an additional 11,642 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company's stock.
Shares of NASDAQ IMUX opened at $1.09 on Wednesday. The firm has a market cap of $98.19 million, a PE ratio of -0.89 and a beta of 1.89. The firm has a fifty day moving average of $1.26 and a 200 day moving average of $1.33. Immunic has a one year low of $0.97 and a one year high of $2.11.
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.